AbbVie Inc. enters the obesity market with GUBamy, a promising amylin analog. Click here to find out why ABBV stock is a Buy.

Novo Nordisk (CSE:NOVOb) (NYSE:NVO) shares slumped Wednesday after Roche (SIX:ROG) struck a $5.3 billion deal to acquire rights to an obesity treatment from Denmark’s Zealand Pharma A/S (CSE:ZELA).

In addition, at the end of January 2025, Novo Nordisk published data from a phase 1b/2a clinical study with amycretin, which beat even my wildest expectations. Learn why I believe Novo Nordisk is ...

Shares of Novo Nordisk (NVO) are sliding in Monday trading after the company announces results for its trial of weight-loss drug CagriSema.

Data on the subcutaneous version of amycretin is due next year, and Novo Nordisk also presented early data on another oral therapy, CBR1 inverse agonist monlunabant (INV-202), which showed a 3% ...

Morgan Stanley notes Novo Nordisk (NVO) disclosed headline data for CagriSema in REDEFINE-2, with a weight loss and safety ...

Novo Nordisk’s shares rose by 3.8% in US markets ... A recent trial of its next-generation obesity treatment, amycretin, showed positive results, temporarily lifting its share price in January.

Novo Nordisk's once-daily oral Amycretin, a GLP-1/Amylin co-agonist, has shown promising results in early trials. With competitive weight loss percentages at various doses compared to other oral ...

The company is also making strides in the development of oral treatments for obesity. Novo Nordisk's once-daily oral Amycretin, a GLP-1/Amylin co-agonist, has shown promising results in early trials.

A subcutaneous version of amycretin also performed well in a phase 1b/2a study. Novo Nordisk seems to have a GLP-1 medicine development engine that grants it an edge against almost any other ...